Project Narrative This work will provide refined trial design, outcome measurement development, statistical tools, etc. (SBIR Phase I) to inform us on an optimal clinical trial design to demonstrate latiglutenase as a therapeutic solution for symptomatic treatment of celiac disease (CD) patients (SBIR Phase II). The primary endpoint will be statistically significant symptomatic improvement relative to placebo for seropositive CD patients as measured using a validated patient-reported outcome (PRO) instrument.
|Effective start/end date||3/8/19 → 10/31/22|
- National Institute of Allergy and Infectious Diseases: $200,524.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.